Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto
Abstract
The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
Claims
exact text as granted — not AI-modified1 . A method of forming bone in vivo comprising implanting a graft composition comprising a collagen matrix and tacrolimus in a subject such that bone forms in the graft.
2 . The method of claim 1 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
3 . A method of forming bone in vivo comprising implanting a graft composition comprising a hydrogel matrix and tacrolimus in a subject such that bone forms in the graft.
4 . The method of claim 3 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
5 . A method of forming bone in vivo comprising implanting a graft composition comprising calcium phosphates and tacrolimus in a subject such that bone forms in the graft.
6 . The method of claim 5 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
7 . The method of claim 5 , wherein said calcium phosphates are hydroxyapatite and tricalcium phosphate.
8 . A method of performing spinal fusion comprising implanting a bone graft composition comprising collagen matrix and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject.
9 . The method of claim 8 , wherein the subject has symptoms of back pain.
10 . The method of claim 8 , wherein the subject is diagnosed with a degenerative disc.
11 . The method of claim 8 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
12 . A method of performing spinal fusion comprising implanting a bone graft composition comprising hydrogel matrix and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject.
13 . The method of claim 12 , wherein the subject has symptoms of back pain.
14 . The method of claim 13 , wherein the subject is diagnosed with a degenerative disc.
15 . The method of claim 12 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
16 . A method of performing spinal fusion comprising implanting a bone graft composition comprising calcium phosphates and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject.
17 . The method of claim 16 , wherein the subject has symptoms of back pain.
18 . The method of claim 16 , wherein the subject is diagnosed with a degenerative disc.
19 . The method of claim 16 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3 of bone graft volume.
20 . The method of claim 16 , wherein said calcium phosphates are hydroxyapatite and tricalcium phosphate said calcium phosphates are hydroxyapatite and tricalcium phosphate.Join the waitlist — get patent alerts
Track US2022054715A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.